SCHEMBL525353

SCHEMBL525353

NC(=S)NCc1cccnc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.74
GAA P10253 1/20 0.71
RECQL P46063 1/20 0.70
CTSL P07711 1/20 0.68
KEAP1 Q14145 1/20 0.64
HTT P42858 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
CYP1A2 P05177 1/20 0.58
CYP2D6 P10635 1/20 0.58
POLB P06746 1/20 0.56
MAPT P10636 3/20 0.55
MAPK1 P28482 1/20 0.55
FES P07332 1/20 0.54
RET P07949 1/20 0.54
MARK3 P27448 1/20 0.54
TYK2 P29597 1/20 0.54
FLT4 P35916 1/20 0.54
SYK P43405 1/20 0.54
CLK2 P49760 1/20 0.54
CLK4 Q9HAZ1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31241520 1.00 ALDH1A1 (0.74) ALDH1A1GAARECQLCTSLKEAP1
SCHEMBL14715315 0.86 ALDH1A1 (0.70) ALDH1A1GAARECQLCTSLKEAP1
SCHEMBL18050211 0.85 ALDH1A1 (0.79) ALDH1A1GAARECQLCTSLKEAP1
SCHEMBL38659518 0.85 ALDH1A1 (1.00) ALDH1A1GAARECQLCTSLKEAP1
SCHEMBL5145645 0.85 ALDH1A1 (1.00) ALDH1A1GAARECQLCTSLKEAP1
Hydrochloric Acid SCHEMBL14714625 0.85 ALDH1A1 (0.68) ALDH1A1GAARECQLCTSLKEAP1
SCHEMBL11355240 0.84 ALDH1A1 (0.77) ALDH1A1GAARECQLCTSLKEAP1
Hydrochloric Acid SCHEMBL8046034 0.83 ALDH1A1 (0.66) ALDH1A1GAARECQLCTSLKEAP1
SCHEMBL525715 0.83 ALDH1A1 (0.56) ALDH1A1GAARECQLCTSLKEAP1
SCHEMBL5180116 0.83 ALDH1A1 (1.00) ALDH1A1GAARECQLCTSLKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS 1998-12-30 WO claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
CN-110938848-B Composition for electrolytic deposition of copper and acid copper electroplating solution 江苏艾森半导体材料股份有限公司 2021-05-11 CN disclosed
CN-110938848-A Composition for electrolytic deposition of copper and acid copper electroplating solution 江苏艾森半导体材料股份有限公司 2020-03-31 CN disclosed
US-9353089-B2 Compositions and methods for the treatment of malaria SAINT LOUIS UNIVERSITY (US) 2016-05-31 US disclosed
US-9150561-B2 Thiazole derivatives and use thereof MERCK SERONO S.A. (CH) 2015-10-06 US disclosed
WO-2014160775-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA SAINT LOUIS UNIVERSITY (US) 2014-10-02 WO disclosed
US-20140296532-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) 2014-10-02 US disclosed
US-20140228365-A1 THIAZOLE DERIVATIVES AND USE THEREOF MERCK SERONO S.A. (CH) 2014-08-14 US disclosed
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US disclosed
EP-1709019-A2 THIAZOLE DERIVATIVES AND USE THEREOF Applied Research Systems ARS Holding N.V. (AN) 2006-10-11 EP disclosed
JP-2006206946-A SILVER PLATING BATH FOR CUPROUS MATERIAL ISHIHARA CHEM CO LTD 2006-08-10 JP disclosed
WO-2005068444-A2 THIAZOLE DERIVATIVES AND USE THEREOF APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2005-07-28 WO disclosed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP disclosed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP disclosed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP disclosed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228365-A1 THIAZOLE DERIVATIVES AND USE THEREOF PF4, TEC, PDGFRB ALDH1A1 234/4885GAA 4479/4885RECQL 3575/4885
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 ALDH1A1 2069/4885GAA 266/4885RECQL 2280/4885
US-20140296532-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA BACE2, DNPEP, ACE ALDH1A1 1822/4885GAA 86/4885RECQL 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.